Why patellofemoral OA needs its own injection pathway

If your OA is specifically in the patellofemoral compartment — the joint between the kneecap and the groove at the front of the thigh bone — you may have wondered whether the injection research actually applies to you. Most large knee OA trials recruited patients with tibiofemoral disease, the compartment between the femur and tibia. That gap in the evidence has now narrowed: a 2025 double-blind RCT by Mekariya et al. enrolled 60 patients with isolated patellofemoral OA and compared two of the main injection options head-to-head, demonstrating that intra-articular injection is an effective nonoperative treatment specifically for this compartment.

Patellofemoral OA has a recognisable day-to-day character. The discomfort tends to sit at the front of the knee — under or around the kneecap — and flares on stairs, deep squats, and prolonged sitting, when patellofemoral contact load is highest. It can co-exist with tibiofemoral OA or present in isolation.

Beyond the evidence question, the anatomy of this compartment also influences how injections should be delivered in practice — something the guide covers in detail further on.

The injection options and who each one suits

Choosing between injection types is less about ranking them and more about matching each agent to the clinical picture. The four main options differ meaningfully in how quickly they act, how long they last, and which patient profiles they suit best.

Corticosteroid

For patients in the middle of an acute flare — severe pain, noticeable swelling, significant restriction — corticosteroid is typically the first-line injection. Relief can begin within 24–72 hours. The trade-off is longevity: effects generally last two weeks to three months, and the frequency should be limited to around three or four injections per year, since repeated use carries a risk of accelerating cartilage degradation. One additional timing constraint matters for anyone considering surgery: receiving a corticosteroid injection within six to seven months of planned knee arthroplasty appears to raise the risk of postoperative infection, so the gap needs careful management if an operation is on the horizon.

Hyaluronic acid (viscosupplementation)

For mild-to-moderate PFOA where the aim is sustained, lower-intensity support over several months, hyaluronic acid is better suited than corticosteroid. It takes ten to fifteen days to reach full effect but may provide relief for up to six months. It is also the preferred option for patients whose cardiovascular profile means anticoagulants cannot be paused — a practical consideration that sometimes rules out PRP. The 2025 Mekariya RCT provides the strongest PFOA-specific trial evidence for this class.

Platelet-rich plasma (PRP)

PRP is generally positioned for patients with Kellgren–Lawrence grade I–III disease who have completed a course of physiotherapy without adequate relief and want to delay or avoid surgery. Effects build gradually over two to four weeks, with outcomes typically peaking at six to twelve months. The evidence base in isolated patellofemoral OA specifically is smaller-series rather than large RCT. PRP is not routinely covered by UK private medical insurance, which is worth factoring in at the planning stage.

Arthrosamid (polyacrylamide hydrogel)

Arthrosamid works differently from the other agents: the hydrogel (2.5% cross-linked polyacrylamide in water) adheres to the synovial membrane as a scaffold rather than dispersing in the joint fluid. A single injection may provide symptom support for up to twelve to twenty-four months. PFOA-specific data remain early-stage — a 2022 case series by Maulana, Cole & Lee, published in the Journal of Arthritis, reported a reduction in patellofemoral bone marrow lesions after one injection — but larger controlled studies are needed. As with PRP, insurance coverage is variable.

PRP combined with hyaluronic acid

Some clinicians now offer PRP and HA together, and emerging evidence suggests the combination may produce better pain relief and functional improvement than either agent alone for patellofemoral OA. The evidence remains preliminary, and this option is best discussed as part of an individual assessment rather than a default pathway.

Why ultrasound guidance matters for this compartment

For the patellofemoral compartment specifically, the answer to 'does it matter how the injection is done?' is yes — and it matters more here than in the knee joint generally.

The patellofemoral space is anatomically distinct and relatively small. Landmark-based ('blind') injection — positioning the needle by feel and surface anatomy alone — carries a real risk of depositing the injectate outside the target compartment. Published accuracy data put ultrasound-guided patellofemoral injections at approximately 95–96% intra-articular accuracy, compared with 78–83% for unguided technique. That gap is clinically meaningful when the entire therapeutic effect depends on the agent reaching the right space.

Real-time imaging also allows the clinician to confirm that the needle tip is not in contact with the cartilage surface or an adjacent tendon — a relevant consideration when the agent is intended to act on the synovial environment or joint fluid.

Patients can reasonably ask, before their appointment, whether ultrasound guidance will be used for their injection and what approach is planned. It is a routine question, and a straightforward one for any experienced practitioner to answer.

What to expect: timelines, aftercare, and realistic outcomes

Injections manage pain; they do not reverse cartilage loss. That distinction shapes what success looks like: a reduction in symptoms sufficient to allow physiotherapy and load management to do the work that chemistry cannot. In PFOA, where quadriceps activation, patellar tracking, and movement patterns all bear on long-term joint health, rehabilitation is the active partner — not an optional follow-on.

The first 48 hours

The post-injection period is straightforward. Reduced loading for the first 48 hours is standard — strenuous activity should be avoided while the agent settles. A temporary post-injection flare (a brief increase in soreness) can occur and typically responds to ice. Most patients begin physiotherapy within two to three days, once the initial discomfort has passed.

Timing rehabilitation to each agent

The onset profiles for each option are covered in the section above. The practical point here is different: plan physiotherapy before the injection appointment, not after. Faster-acting agents allow PT to begin almost immediately; slower-building options such as PRP mean the therapeutic window opens gradually over several weeks. Booking both in advance avoids a gap in momentum and keeps the recovery moving.

What the evidence shows

In the 2025 Mekariya RCT of 60 patients with isolated PFOA, both hyaluronic acid and corticosteroid produced statistically significant improvements in VAS pain scores and WOMAC functional scores across a six-month follow-up. Those outcome measures capture what matters to patients day to day — managing stairs, sustaining a seated position, rising from a chair — not pain reduction in isolation.

Six-month data for corticosteroid and HA in isolated PFOA are robust. Long-term comparative evidence beyond six months in this specific compartment remains limited; outcomes thereafter depend substantially on how actively patients engage with rehabilitation during the pain-reduced window.

When injection therapy is not enough on its own

Injections act on the chemical and inflammatory environment of the joint; they cannot reposition the kneecap, tighten a lax medial patellofemoral ligament, or alter trochlear geometry. Where patellar malalignment, MPFL injury, or trochlear dysplasia is contributing to symptoms, those mechanical factors need assessment and management in their own right — injection alone may produce only partial or short-lived relief if the underlying biomechanics remain uncorrected.

This is worth establishing at assessment rather than discovering after two or three injection cycles. If imaging or examination points to a meaningful structural component, the plan should address that alongside or before injection therapy, not treat it as a separate problem to come back to later.

The corticosteroid timing caution covered in the injection options section above applies directly here too: if surgery is already under active consideration, both agent choice and scheduling need to reflect where in the pathway the patient actually sits.

If injections are not delivering

The Kuwabara (2022) review sets out a stepwise surgical framework for PFOA: arthroscopic assessment of patellofemoral cartilage first, followed by tibial tubercle osteotomy (TTO) for active or younger patients, and patellofemoral arthroplasty (PFA) for severe, refractory cases. No head-to-head RCT has yet compared injection directly against surgery in isolated PFOA, so the decision to escalate remains clinical rather than protocol-driven.

A practical signal to revisit the plan is two successive injections providing progressively shorter windows of meaningful relief — particularly when paired with imaging evidence of advancing cartilage loss. That pattern, rather than any fixed count of injections tried, is the usual prompt for a surgical referral discussion.

Checking your suitability for patellofemoral injection

A structured assessment typically covers four areas: OA severity on imaging (Kellgren-Lawrence grade), symptom pattern and treatment history, cardiovascular and medication profile, and whether structural factors such as patellar malalignment or trochlear dysplasia have already been identified on examination or imaging.

Most patients suited to injection therapy share a common profile:

• A confirmed PFOA diagnosis supported by imaging
• Symptoms not fully controlled by physiotherapy and load management alone
• No surgery planned within six to seven months (particularly relevant if corticosteroid is under consideration)
• Realistic expectations: pain reduction sufficient to support rehabilitation, not restoration of lost cartilage

Those four factors together determine which injection class is appropriate and whether the timing is right — they cannot be reliably judged from symptom description alone. The structural and medication picture matters as much as the pain score itself.

For patients at this stage, the suitability assessment on amsk.co.uk is structured around exactly these questions — the clearest way to find out whether injection is the right next step and, if so, which approach fits the individual clinical picture.